| abstract |
Hybrid molecules comprising a vitamin D receptor agonist moiety and an HDAC inhibitor moiety are described herein. The HDAC inhibitor moiety can be derived from an HDAC inhibitor comprising a functionality selected from the group consisting of an N-hydroxyformate, a thioglycolate amide, a glycinamide, a bromoacetamide, a sulphonamide, a sulfamide, an alpha-keto ester or amide, or an orthoaminoanilide These hybrid molecules can be used in the treatment of conditions such as bacterial infections, cancer, inflammation and auto-immune diseases or for the induction of wound healing. Specific hybrid molecules of the present invention. have the following structures, Formula (I) and Formula (II). |